



# Point-of-care lung ultrasound assessment for risk stratification and therapy guiding in COVID-19 patients: a prospective noninterventional study

Jorge Rubio-Gracia<sup>1,2</sup>, Ignacio Giménez-López<sup>2,3,4</sup>, Vanesa Garcés-Horna<sup>1,2</sup>, Daniel López-Delgado<sup>1</sup>, Jose Luis Sierra-Monzón<sup>2,5</sup>, Luis Martínez-Lostao<sup>2,4,6</sup>, Claudia Josa-Laorden<sup>1,2</sup>, Fernando Ruiz-Laiglesia<sup>1,2</sup>, Juan Ignacio Pérez-Calvo<sup>1,2,3,4</sup>, Silvia Crespo-Aznarez<sup>1</sup>, Javier García-Lafuente<sup>1</sup>, Natacha Peña Fresneda<sup>2,4</sup>, Beatriz Amores Arriaga<sup>1,2</sup>, Borja Gracia-Tello<sup>1,2,6</sup> and Marta Sánchez-Marteles<sup>1,2</sup>

<sup>1</sup>Internal Medicine Dept, Clinical Hospital “Lozano Blesa”, Zaragoza, Spain. <sup>2</sup>Aragon Health Research Institute, Zaragoza, Spain. <sup>3</sup>School of Medicine, Zaragoza University, Zaragoza, Spain. <sup>4</sup>Center for Biomedical Research of Aragon, Zaragoza, Spain. <sup>5</sup>Infectious Diseases Dept, Clinical Hospital “Lozano Blesa”, Zaragoza, Spain. <sup>6</sup>Immunology Dept, Clinical Hospital “Lozano Blesa”, Zaragoza, Spain.

Corresponding author: Jorge Rubio-Gracia ([jorgerubiogracia@gmail.com](mailto:jorgerubiogracia@gmail.com))



Shareable abstract (@ERSpublications)

Lung injury caused by coronavirus disease 2019 (COVID-19) can be measured through lung ultrasound. Lung ultrasound identifies COVID-19 patients at a higher risk of complications, and could support clinical-decision making in COVID-19 patients. <http://bit.ly/3cQiz6K>

**Cite this article as:** Rubio-Gracia J, Giménez-López I, Garcés-Horna V, et al. Point-of-care lung ultrasound assessment for risk stratification and therapy guiding in COVID-19 patients: a prospective noninterventional study. *Eur Respir J* 2021; 58: 2004283 [DOI: 10.1183/13993003.04283-2020].

This single-page version can be shared freely online.

Copyright ©The authors 2021.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

This article has supplementary material available from [erj.ersjournals.com](http://erj.ersjournals.com)

Received: 20 Nov 2020  
Accepted: 31 Jan 2021

## Abstract

**Background** Lung ultrasound is feasible for assessing lung injury caused by coronavirus disease 2019 (COVID-19). However, the prognostic meaning and time-line changes of lung injury assessed by lung ultrasound in COVID-19 hospitalised patients are unknown.

**Methods** Prospective cohort study designed to analyse prognostic value of lung ultrasound in COVID-19 patients by using a quantitative scale (lung ultrasound Zaragoza (LUZ)-score) during the first 72 h after admission. The primary end-point was in-hospital death and/or admission to the intensive care unit. Total length of hospital stay, increase of oxygen flow and escalation of medical treatment during the first 72 h were secondary end-points.

**Results** 130 patients were included in the final analysis; mean±SD age was 56.7±13.5 years. Median (interquartile range) time from the beginning of symptoms to admission was 6 (4–9) days. Lung injury assessed by LUZ-score did not differ during the first 72 h (21 (16–26) points at admission versus 20 (16–27) points at 72 h; p=0.183). In univariable logistic regression analysis, estimated arterial oxygen tension/inspiratory oxygen fraction ratio (PAFI) (hazard ratio 0.99, 95% CI 0.98–0.99; p=0.027) and LUZ-score >22 points (5.45, 1.42–20.90; p=0.013) were predictors for the primary end-point.

**Conclusions** LUZ-score is an easy, simple and fast point-of-care ultrasound tool to identify patients with severe lung injury due to COVID-19, upon admission. Baseline score is predictive of severity along the whole period of hospitalisation. The score facilitates early implementation or intensification of treatment for COVID-19 infection. LUZ-score may be combined with clinical variables (as estimated by PAFI) to further refine risk stratification.

